Aptevo Therapeutics (APVO) was advancing almost 7% Wednesday after the company said the first patient with acute myeloid leukemia dosed in a phase 1b/2 trial evaluating its mipletamig immune-oncology candidate together with standard of care venetoclax and azacitidine achieved a 90% reduction in leukemic blasts within the first 30 days of treatment.
The encouraging initial results continue the overall efficacy, safety and tolerability seen for mipletamig in prior studies, alongside evidence of durable remission, the biotechnology company said.
The open-label study is evaluating the combination of mipletamig with standard of care treatments as frontline combination therapy for leukemia in as many of 39 patients who will be treated across five dosing levels.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。